RxDoctor Payments Data

McGarrett Groth, DO

Family Medicine · Attchison, KSNPI 1922236470

Payments from drug & device makers

$184in general payments, 2019–2025

Across 11 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$96
  • Genentech USA, Inc.$19
  • Novo Nordisk$18
  • AstraZeneca$18
  • Pfizer$16
  • Amarin Pharma, Inc.$13
  • plus $4 from 1 others

What the payments were for

  • Food & beverage$18098%
  • Education$42%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)5$96
Genentech USA, Inc.1$19
Novo Nordisk1$18
AstraZeneca1$18
Pfizer1$16
Amarin Pharma, Inc.1$13
CSL Behring1$4

How this compares

$184 in reported general payments places this provider in the 35th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$51,228
Medicare patients
472
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate23$25,982
RybelsusSemaglutide19$17,475
OzempicSemaglutide16$16,466
TrulicityDulaglutide16$15,246
EliquisApixaban13$8,607
JardianceEmpagliflozin11$6,560
Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol13$5,613
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$4,687
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,172
Novolog FlexpenInsulin Aspart11$1,674
Albuterol Sulfate HfaAlbuterol Sulfate55$1,651
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,111
Celecoxib12$1,076
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$943
Pantoprazole Sodium61$736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$18$33,94235 claims
PfizerEliquis$16$8,60713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Attchison

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →